.Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AG02_Moclobemide.Moclobemide

Information

Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA) used primarily as an antidepressant for the treatment of major depressive disorder and social phobia. It is approved in some countries for these indications, though not in the United States.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers, both sexes, aged 18-65 years, after single oral dose.

References

1. Fuseau, E, et al., & Ibbotson, T (2002). Clinical pharmacokinetics of intranasal sumatriptan. Clinical pharmacokinetics 41(11) 801–811. DOI:10.2165/00003088-200241110-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12190330

2. Schoerlin, MP, & Guentert, TW (1989). [Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human]. Psychiatrische Praxis 16 Suppl 1 11–17. PUBMED:https://pubmed.ncbi.nlm.nih.gov/2685852

3. Holford, NH, et al., & Banken, L (1994). Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. British journal of clinical pharmacology 37(5) 433–439. DOI:10.1111/j.1365-2125.1994.tb05710.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/7519866

Revisions

• 06/2025 initial generated model